<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00411372</url>
  </required_header>
  <id_info>
    <org_study_id>SCO105782</org_study_id>
    <nct_id>NCT00411372</nct_id>
  </id_info>
  <brief_title>Shortness Of Breath Questionnaire Validation Study</brief_title>
  <official_title>A Randomized, Double-blind, Parallel-group Study of Fluticasone Propionate/Salmeterol Combination (FSC 250/50mcg) Twice Daily and Salmeterol (SAL 50mcg) Twice Daily to Validate a New Shortness of Breath Questionnaire in Patients With Chronic Obstructive Pulmonary Disease (COPD)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>GlaxoSmithKline</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>GlaxoSmithKline</source>
  <brief_summary>
    <textblock>
      This study will last for approximately 8 weeks and will involve 4 visits. The study is being
      carried out to validate a shortness of breath questionnaire
    </textblock>
  </brief_summary>
  <overall_status>Withdrawn</overall_status>
  <why_stopped>
    No subjects enrolled. Study was canceled before active
  </why_stopped>
  <start_date>November 2006</start_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double</masking>
  </study_design_info>
  <primary_outcome>
    <measure>The objective of this study is the validation of the Shortness of Breath Questionnaire in subjects with COPD</measure>
  </primary_outcome>
  <secondary_outcome>
    <measure>spirometry (FEV1, FVC, IC)</measure>
  </secondary_outcome>
  <secondary_outcome>
    <measure>diary card data</measure>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Health Outcomes (Chronic Respiratory Questionnaire - SAS, Clinical Global Impression of Dyspnea Severity, Patient Global Assessment of Change Question, Clinical Global Impression of Change Question</measure>
  </secondary_outcome>
  <enrollment type="Actual">0</enrollment>
  <condition>Pulmonary Disease, Chronic Obstructive</condition>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>fluticasone propionate/salmeterol 250/50mcg combination, salmeterol 50mcg</intervention_name>
    <other_name>fluticasone propionate/salmeterol 250/50mcg combination</other_name>
    <other_name>salmeterol 50mcg</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion criteria:

          -  Diagnosis of COPD

        Exclusion Criteria:

          -  Women who are pregnant or lactating.

          -  Subjects with a primary diagnosis of asthma. (Subjects with a prior history of asthma
             are eligible if COPD is currently their primary diagnosis)

          -  Has a respiratory disorder other than COPD (e.g., bronchiectasis, sarcoidosis, active
             tuberculosis, lung fibrosis), including subjects with a diagnosis of
             alpha-1-antitrypsin deficiency.

          -  Subjects with lung volume reduction surgery or lung transplant within the previous 12
             months.

          -  Chest X-ray (posterior-anterior) or CT scan reveals evidence of clinically significant
             abnormalities not believed to be due to the presence of COPD. A chest X-ray must be
             taken if the subject has not had one within 12 months of the Screening Visit.

          -  Subjects with clinically significant cardiovascular (including clinically significant
             ECG abnormalities, CHF), neurological, psychiatric, renal, immunological,
             endocrine(including uncontrolled diabetes or thyroid disease) or hematological
             abnormalities that is uncontrolled.

          -  Subjects with carcinoma that has not been in complete remission for at least 5 years.
             Carcinoma in situ of the cervix, squamous cell carcinoma of the skin and basal cell
             carcinoma would not be considered exclusion criteria if the subject was considered
             cured in less than 5 years since diagnosis.

          -  Any adverse reaction including immediate or delayed hypersensitivity to any
             betaagonist, sympathomimetic drug, or intranasal, inhaled, or oral corticosteroid
             including any components of the formulations (e.g. lactose or milk protein).

          -  Initiation of systemic beta-blocker medications at any time during the study. Systemic
             beta-blockers and beta-blocker eye drops are allowed for those subjects who have been
             on a stable regimen for at least 30 days prior to screening and judged capable to
             continue this regimen until discharged from the study.

          -  Subject continues on any prohibited medications, as listed in Section 5.6.2.

          -  Subject is receiving treatment with long-term oxygen therapy (LTOT), defined as
             inSection 5.6.2.

          -  Use of immunosuppressive medications at any time during the study. Immunotherapy for
             the treatment of allergies is allowed during the study provided that the subject has
             received a constant dose for 30 days prior to the Screening Visit and the dose is
             maintained during the study.

          -  Subjects who are medically unable to withhold their albuterol or ipratropium for the 6
             hour period required prior to administration of questionnaires and spirometry at each
             study visit.

          -  An infection of the upper or lower respiratory tract requiring treatment with
             antibiotics 14 days prior to the Screening Visit.

          -  Subjects who require nocturnal positive pressure.

          -  Enrolled in or discontinuation of a pulmonary rehabilitation program within 30 days of
             Visit 1. Subjects who are enrolled in a pulmonary rehabilitation program at study
             start should maintain participation in the program for the duration of the study.

          -  Use of any investigational drug within 30 days of Visit 1 or at any time during the
             study is not allowed.

          -  Subjects unable to comply with study procedures.

          -  Study investigators, sub-investigators, study coordinators, employees of a
             participating investigator or immediate family members of the aforementioned are
             excluded from participation in this study.

          -  Subjects with a history of psychiatric disease, intellectual deficiency, poor
             motivation, substance abuse, (including drug and alcohol), or other conditions, which
             will limit the validity of informed consent to participate in the study.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>N/A</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>GSK Clinical Trials</last_name>
    <role>Study Director</role>
    <affiliation>GlaxoSmithKline</affiliation>
  </overall_official>
  <removed_countries>
    <country>United States</country>
  </removed_countries>
  <verification_date>February 2015</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>December 13, 2006</study_first_submitted>
  <study_first_submitted_qc>December 13, 2006</study_first_submitted_qc>
  <study_first_posted type="Estimate">December 14, 2006</study_first_posted>
  <last_update_submitted>February 19, 2015</last_update_submitted>
  <last_update_submitted_qc>February 19, 2015</last_update_submitted_qc>
  <last_update_posted type="Estimate">February 23, 2015</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Questionnaire</keyword>
  <keyword>COPD</keyword>
  <keyword>Shortness of Breath</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Lung Diseases</mesh_term>
    <mesh_term>Pulmonary Disease, Chronic Obstructive</mesh_term>
    <mesh_term>Chronic Disease</mesh_term>
    <mesh_term>Dyspnea</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Fluticasone</mesh_term>
    <mesh_term>Salmeterol Xinafoate</mesh_term>
    <mesh_term>Fluticasone Propionate, Salmeterol Xinafoate Drug Combination</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

